Overview PRS-343 in HER2-Positive Solid Tumors Status: Recruiting Trial end date: 2021-09-01 Target enrollment: Participant gender: Summary A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors. Phase: Phase 1 Details Lead Sponsor: Pieris Pharmaceuticals, Inc.